Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
If serum values were decisive, even patients with neurological involvement could suffice with the maintenance dose of one injection every two months after the initial loading dose
For weight loss, the effects are typically seen over time, especially when combined with a healthy diet and exercise routine
We recommend up to 2 times per week
Higher dosing: Some protocols use 500-750mcg twice daily for more severe injuries or faster results
The Cellular Mechanisms: How GHK-Biotin Works on the Scalp Extending the Anagen Phase Through Growth Factor Modulation One of the most significant and well-documented actions of GHK-Cu class peptides on the scalp is their ability to modulate the cytokines and growth factors that govern the hair cycle
